AstraZeneca PLC needs to hit upcoming regulatory milestones and data readouts for pipeline assets to ease pressure on the current portfolio, which faced headwinds in the first quarter in categories like diabetes, respiratory and cardiovascular disease.
The company has several important regulatory events ahead in 2017. Most notably, US FDA action is expected on the PD-L1...








